Skip to content

Nurix

Inside The Science
Advancing Our Pipeline
- Pipeline
- Clinical Trials
Learn About Us
Work at Nurix
- Our Culture
- Explore Jobs

Nurix

Inside The Science
Advancing Our Pipeline
- Pipeline
- Clinical Trials
Learn About Us
Work at Nurix
- Our Culture
- Explore Jobs

Overcoming Acquired Inhibitor Resistance & Addressing Novel Scaffolding Functions of BTK in the Clinic

By AldenMC Production / October 31, 2023

Post navigation

Roy Baynes, MB.Bch., M.Med., Ph.D.

NX-1607, a small molecule inhibitor of CBL-B, enhances anti-PD-1-mediated tumor growth inhibition by reshaping intratumoral innate and adaptive immune responses

WHERE SCIENCE EXPANDS POSSIBILITIES

Inside The Science

DEL-AI Discovery Engine
Targeted Protein Degradation
Resource Library

Advancing Our Pipeline

Pipeline
Clinical Trials

Learn About Us

Our Story
Leadership
Partnering
Contact Us

Work at Nurix

Our Culture
Explore Jobs

For Investors

News & Events
Financial Information
Stock Information
Corporate Governance
FAQs
Investor Contact

For Patients

Resources

©2025 Nurix Therapeutics, Inc.

You are now leaving the nurixtx.com website. This link will take you to a website to which our Privacy Policy does not apply. You are solely responsible for your interactions with that website.

Cancel

Continue